# Veloxis Pharmaceuticals A/S

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/veloxis-pharmaceuticals-a-s

- Industry: Pharmaceuticals
- Headquarters: Copenhagen, Denmark
- Website: www.veloxis.com
- Total disclosed funding: $18M
- Latest round: Series C (May 17, 2005)
- Investors on record: 5

## About

Veloxis Pharmaceuticals A/S is dedicated to developing innovative therapies for enhancing transplant healthcare, focusing on immunosuppressive solutions that significantly improve patient outcomes during the transplantation process.Founded in 2007, Veloxis Pharmaceuticals A/S, located in Copenhagen, Denmark, specializes in creating therapies for the transplant healthcare sector. The company was co-founded by Mohammad Sohail. In a notable pivot, Veloxis was acquired in a TRADE SALE by Asahi Kasei Corporation for DKK 8,900.00 mn, marking a significant milestone in its operational strategy. The company has completed a total of 8 deals, indicating active engagement in the specialty pharmaceuticals market.Veloxis Pharmaceuticals focuses on developing innovative therapies aimed at improving transplant healthcare for both providers and patients. Its flagship product, pegrizeprument (VEL-101), acts as a subcutaneous CD28 co-stimulation blocker for maintenance immunosuppression in kidney transplantation. This investigational drug addresses the challenges of effective immunosuppressive therapies, targeting hospitals and clinics that specialize in organ transplants. The company's products are primarily marketed in North America and select European regions, demonstrating a commitment to enhancing global healthcare.In 2022, Veloxis Pharmaceuticals reported zero revenue, while in 2023, it recorded an EBITDA of DKK -214,000. The company's revenue model is primarily based on the sale of its investigational immunosuppressive drug, pegrizeprument, through partnerships with healthcare providers, including transplant centers. These partnerships often involve direct engagements to supply therapies as part of patient treatment regimens, focusing on integration into existing healthcare protocols.Veloxis Pharmaceuticals aims to expand its product offerings and market reach, particularly through the development of new therapies designed for transplant patients. The company is targeting growth in additional markets across Europe and North America by leveraging its recent funding from the TRADE SALE to enhance its product development and marketing efforts. The exit of Adamant Biomedical Investments AG and Alta Partners from their stake suggests a strategic repositioning within the market, facilitating new opportunities for future initiatives.

## Funding rounds

- Series C, May 17, 2005, $18M — Alta Partners, NB Capital, Novo Holdings, Lundbeckfond Ventures, Adamant Biomedical Investments AG

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C
- NB Capital (https://capitalatlas.ai/funds/nb-capital) — Series C
- Novo Holdings — Series C
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series C
- Adamant Biomedical Investments AG — Series C